신경내분비종양 치료 시장 : 약제 클래스별, 적응증별, 유통 채널별 및 지역별

Neuroendocrine Tumor Treatment Market is estimated to be valued at USD 3.88 Bn in 2026 and is expected to reach USD 6.00 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.4% from 2026 to 2033.

Neuroendocrine tumors (NETs) result from the abnormal growth of neoplasms that originate from cells of various endocrine glands and nervous systems. Though most of these are benign, some tend to become malignant and may turn cancerous in the long term. Neuroendocrine tumors are generally infected initially in intestine, which are often known as carcinoid tumors. Pancreas is the second most prime organ in the body, where growth of NET is common. There are number of clinical trials are ongoing to develop the novel therapy or drugs for the treatment of the pancreatic neuroendocrine tumors in adult patients.

Market Dynamics

The rising incidence of GI and lung neuroendocrine tumors is a key factor that is expected to fuel growth of the global neuroendocrine tumor treatment market over the forecast period. For instance, according to data published in American Society of Clinical Oncology (ASCO) in 2019, estimated 12,000 people in the U.S. are diagnosed with a NET, each year. And around 170,000 people are living currently with NET. The 5-year survival for NET of the small intestine was 86.2%, 82.7% for stomach, and 67.4% for colon. Apart from GI and Lung Neuroendocrine, there are other factors, which influence NET include hormonal imbalance at pituitsary gland and thyroid gland. The rising demand for various imagining techniques in North America and Europe is expected to fuel growth of the global market over the forecast period. Drug portfolio expansion and development of new products that can inhibit excess hormone production are some of the other factors that are expected to augment growth of the global neuroendocrine tumor treatment market over the forecast period.

Key features of the study:

• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global neuroendocrine tumor treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
• The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for neuroendocrine tumor treatment market, research and consulting firms, new entrants, and financial analysts
• Various strategy matrices used in analyzing the neuroendocrine tumor treatment market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

• Global Neuroendocrine Tumor Treatment Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
• Somatostatin Analogues (SSAs)
  • Octreotide
  • Lanreotide
  • Others
• Targeted Therapy
• Chemotherapy
• Others
• Global Neuroendocrine Tumor Treatment Market, By Indication (Revenue, USD Bn, 2021 - 2033)
• Gastrointestinal NET
• Lung NET
• Pancreatic NET
• Other NET
• Global Neuroendocrine Tumor Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
• Hospitals
• Oncology Centers
• Others
• Global Neuroendocrine Tumor Treatment Market, By Region (Revenue, USD Bn, 2021 - 2033)
• North America
  • By Treatment Type:
    • Somatostatin Analogues (SSAs)
      • Octreotide
      • Lanreotide
      • Others
    • Targeted Therapy
    • Chemotherapy
    • Others
  • By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Other NET
  • By End User
    • Hospitals
    • Oncology Centers
    • Others
  • By Country:
    • U.S.
    • Canada
• Europe
  • By Treatment Type:
    • Somatostatin Analogues (SSAs)
      • Octreotide
      • Lanreotide
      • Others
    • Targeted Therapy
    • Chemotherapy
    • Others
  • By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Other NET
  • By End User
    • Hospitals
    • Oncology Centers
    • Others
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
• Asia Pacific
  • By Treatment Type:
    • Somatostatin Analogues (SSAs)
      • Octreotide
      • Lanreotide
      • Others
    • Targeted Therapy
    • Chemotherapy
    • Others
  • By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Other NET
  • By End User
    • Hospitals
    • Oncology Centers
    • Others
  • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • By Treatment Type:
    • Somatostatin Analogues (SSAs)
      • Octreotide
      • Lanreotide
      • Others
    • Targeted Therapy
    • Chemotherapy
    • Others
  • By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Other NET
  • By End User
    • Hospitals
    • Oncology Centers
    • Others
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • By Treatment Type:
    • Somatostatin Analogues (SSAs)
      • Octreotide
      • Lanreotide
      • Others
    • Targeted Therapy
    • Chemotherapy
    • Others
  • By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Other NET
  • By End User
    • Hospitals
    • Oncology Centers
    • Others
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • By Treatment Type:
    • Somatostatin Analogues (SSAs)
      • Octreotide
      • Lanreotide
      • Others
    • Targeted Therapy
    • Chemotherapy
    • Others
  • By Indication:
    • Gastrointestinal NET
    • Lung NET
    • Pancreatic NET
    • Other NET
  • By End User
    • Hospitals
    • Oncology Centers
    • Others
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
• Pfizer Inc*
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Future Plans
• Novartis AG
• Ispen
• Advanced Accelerator Applications
• Tarveda Therapeutics
• Progenics Pharmaceuticals, Inc.
• Hutchison Medipharma Limited
• Dauntless Pharmaceuticals Inc.
• Exelixis, Inc.

"*" marked represents similar segmentation in other categories in the respective section

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Recent Trends
• Recent Launches and Approvals
• Mergers, Acquisitions, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis
• PORTER's Analysis

4. Global Neuroendocrine Tumor Treatment Market, By Drug Class, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Somatostatin Analogs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Targeted Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends

5. Global Neuroendocrine Tumor Treatment Market, By Indication, 2021- 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Gastrointestinal NET
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Lung NET
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Pancreatic NET
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends

6. Global Neuroendocrine Tumor Treatment Market, By Distribution Channel, 2021- 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
  • Segment Trends

7. Global Neuroendocrine Tumor Treatment Market, By Region, 2021-2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 -2033, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Ispen
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Advanced Accelerator Applications
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Tarveda Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Progenics Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Hutchison Medipharma Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Dauntless Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Exelixis, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
• Analysts' Views

9. Section

• References
• Research Methodology
• About us and Sales Contact